Randomized, Double-blind, Placebo-controlled Phase 2 Trial of ТВ/Flu-05Е Intranasal Vector Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years

The aim of the study is to investigate immunogenicity and safety of the TB/Flu-05E single-dose intranasal vaccine for the prevention of Tuberculosis infection in BCG-vaccinated Volunteers aged 18-50 years

Start Date13 Dec 2023

Sponsor / Collaborator

Research Institute of Influenza

[+1]

NCT06890429

/ CompletedPhase 2IIT

Randomized, Double-blind, Placebo-controlled Phase 2 Trial of RSV/Flu-01E Vaccine for the Prevention of Respiratory Syncytial Virus Infection in Volunteers Over 60 Years

The aim of the study is to investigate immunogenicity and safety of the RSV/Flu-01E intranasal vaccine for the prevention of respiratory syncytial virus infection in volunteers over 60 years

Start Date07 Dec 2023

Sponsor / Collaborator

Research Institute of Influenza

[+1]

NCT05945498

/ CompletedPhase 1IIT

Randomized, Double-blind, Placebo-controlled Phase 1 Trial of ТВ/Flu-05Е Intranasal Vector Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50

The aim of the study is to investigate safety, reactogenicity and immunogenicity of the TB/Flu-05E single-dose intranasal vaccine for the prevention of Tuberculosis infection in BCG-vaccinated Volunteers aged 18-50 years.

Start Date10 May 2023

Sponsor / Collaborator

Research Institute of Influenza

100 Clinical Results associated with Research Institute of Influenza

0 Patents (Medical) associated with Research Institute of Influenza

142

Literatures (Medical) associated with Research Institute of Influenza

01 Mar 2025·Immunity, Inflammation and Disease

Impact of COVID‐19 on Respiratory Virus Infections in Children, Japan, 2018–2023

Article

Author: Fujisaki, Seiichiro ; Senda, Ryuichi ; Matsuzaki, Yoko ; Ozawa, Hiroki ; Momoki, Tomoko ; Kumazaki, Makoto ; Tanaka, Nobuko ; Nakauchi, Mina ; Shimizu, Kohei ; Okubo, Ichiro ; Kawakami, Chiharu ; Takashita, Emi ; Hasegawa, Hideki ; Morita, Hiroko ; Watanabe, Shinji ; Saikusa, Miwako ; Miura, Hideka ; Watanabe, Kayo ; Nagata, Shiho ; Usuku, Shuzo ; Kawaoka, Yoshihiro

ABSTRACTBackgroundCOVID‐19, caused by SARS‐CoV‐2, was first documented in Japan in January 2020. We previously reported an increased risk of rhinovirus infections among children during the early phase of the COVID‐19 pandemic. Here, we assessed the impact of COVID‐19 on respiratory virus infections after SARS‐CoV‐2 spread nationwide.MethodsWe analyzed clinical specimens from 4012 patients with respiratory infections in Yokohama, Japan from January 2018 to April 2023.ResultsAmong 15 representative respiratory viruses we detected (influenza virus, rhinovirus, coxsackievirus, echovirus, enterovirus, human coronavirus 229E, HKU1, NL63, and OC43, human metapneumovirus, human parainfluenza virus, human parechovirus, RSV, human adenovirus, human bocavirus, human parvovirus B19, herpes simplex virus type 1, and varicella‐zoster virus), influenza was most affected by the COVID‐19 pandemic, with no influenza viruses detected for nearly 3 years.ConclusionsThe decrease in influenza infections following the emergence of SARS‐CoV‐2 may have contributed to the previously reported increase in rhinovirus infections. The rhinovirus outbreak, rather than SARS‐CoV‐2, may have contributed to the decrease in enveloped virus infections (RSV, parainfluenza viruses, metapneumovirus, and coronavirus 229E, HKU1, NL63, and OC43), possibly due to negative virus‐virus interactions.

25 Jul 2024·Briefings in Bioinformatics

CAIM: coverage-based analysis for identification of microbiome

Article

Author: Jenjaroenpun, Piroon ; Pomyen, Yotsawat ; Wongsurawat, Thidathip ; Acheampong, Daniel A ; Chuaypen, Natthaya ; Kandel, Sangam ; Kusonmano, Kanthida ; Kunadirek, Pattapon ; Kurilung, Alongkorn ; Nookaew, Intawat

AbstractAccurate taxonomic profiling of microbial taxa in a metagenomic sample is vital to gain insights into microbial ecology. Recent advancements in sequencing technologies have contributed tremendously toward understanding these microbes at species resolution through a whole shotgun metagenomic approach. In this study, we developed a new bioinformatics tool, coverage-based analysis for identification of microbiome (CAIM), for accurate taxonomic classification and quantification within both long- and short-read metagenomic samples using an alignment-based method. CAIM depends on two different containment techniques to identify species in metagenomic samples using their genome coverage information to filter out false positives rather than the traditional approach of relative abundance. In addition, we propose a nucleotide-count–based abundance estimation, which yield lesser root mean square error than the traditional read-count approach. We evaluated the performance of CAIM on 28 metagenomic mock communities and 2 synthetic datasets by comparing it with other top-performing tools. CAIM maintained a consistently good performance across datasets in identifying microbial taxa and in estimating relative abundances than other tools. CAIM was then applied to a real dataset sequenced on both Nanopore (with and without amplification) and Illumina sequencing platforms and found high similarity of taxonomic profiles between the sequencing platforms. Lastly, CAIM was applied to fecal shotgun metagenomic datasets of 232 colorectal cancer patients and 229 controls obtained from 4 different countries and 44 primary liver cancer patients and 76 controls. The predictive performance of models using the genome-coverage cutoff was better than those using the relative-abundance cutoffs in discriminating colorectal cancer and primary liver cancer patients from healthy controls with a highly confident species markers.

01 Jun 2024·Influenza and Other Respiratory Viruses

Monitoring Influenza C and D Viruses in Patients With Respiratory Diseases in Japan, January 2018 to March 2023

Article

Author: Miura, Hideka ; Watanabe, Shinji ; Watanabe, Kayo ; Kumazaki, Makoto ; Saikusa, Miwako ; Matsuzaki, Yoko ; Tanaka, Nobuko ; Senda, Ryuichi ; Momoki, Tomoko ; Kawaoka, Yoshihiro ; Takashita, Emi ; Ozawa, Hiroki ; Morita, Hiroko ; Usuku, Shuzo ; Shimizu, Kohei ; Nagata, Shiho ; Kawakami, Chiharu ; Fujisaki, Seiichiro ; Okubo, Ichiro ; Hasegawa, Hideki

ABSTRACTBackgroundInfluenza viruses can cause zoonotic infections that pose public health risks. Surveillance of influenza A and B viruses is conducted globally; however, information on influenza C and D viruses is limited. Longitudinal monitoring of influenza C virus in humans has been conducted in several countries, but there has been no long‐term monitoring of influenza D virus in humans. The public health risks associated with the influenza D virus therefore remain unknown.MethodsWe established a duplex real‐time RT‐PCR to detect influenza C and D viruses and analyzed respiratory specimens collected from 2144 patients in Japan with respiratory diseases between January 2018 and March 2023. We isolated viruses and conducted hemagglutination inhibition tests to examine antigenicity and focus reduction assays to determine susceptibility to the cap‐dependent endonuclease inhibitor baloxavir marboxil.ResultsWe detected three influenza C viruses belonging to the C/Kanagawa‐ or C/Sao Paulo‐lineages, which recently circulated globally. None of the specimens was positive for the influenza D virus. The C/Yokohama/1/2022 strain, isolated from the specimen with the highest viral RNA load and belonging to the C/Kanagawa‐lineage, showed similar antigenicity to the reference C/Kanagawa‐lineage strain and was susceptible to baloxavir.ConclusionsOur duplex real‐time RT‐PCR is useful for the simultaneous detection of influenza C and D viruses from the same specimen. Adding the influenza D virus to the monitoring of the influenza C virus would help in assessing the public health risks posed by this virus.

100 Deals associated with Research Institute of Influenza

100 Translational Medicine associated with Research Institute of Influenza

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 09 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

TB/Flu-05E vaccine(Research Institute of Influenza)	Tuberculosis More	Phase 2
RSV/Flu-01E	Respiratory Syncytial Virus Infections More	Phase 2
GamEvac-Lyo(Research Institute of Influenza, Sankt-Peterburg, Russian Federation)	-	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis